Medications prescribed by licensed physicians

Vardenafil is a member of the medication class known as phosphodiesterase type 5 (PDE5) inhibitors, which is frequently used to treat erectile dysfunction (ED). Like sildenafil and tadalafil, it is a selective phosphodiesterase (PDE) type 5 inhibitor. Unlike several ED medications, this family of medicines does not suppress prostaglandins (e.g., alprostadil). PDE5 is more specifically targeted by vardenafil and tadalafil than PDE6, which is found in the retina. Less visual side effects like those experienced by people using sildenafil as a result. Vardenafil may have the advantage of reaching its peak plasma concentration earlier than sildenafil and tadalafil, which could lead to a quicker onset of effect. 80 percent of the males who participated in an analysis of 580 patients reported having better erections, and the ability to finish a sexual encounter with ejaculation also improved. It has also been shown to be effective in treating diabetics and men who have undergone radical prostatectomy. Oral phosphodiesterase type 5 inhibitors (PDE5 inhibitor) are regarded as first-line therapy for treating ED. 1 In August 2003, the FDA authorized the erectile dysfunction drug vardenafil. The FDA authorized an orally disintegrating tablet in June 2010.